IAVI-supported candidates
Below is a list of candidates that IAVI is supporting. To see IAVI-led candidates, visit our main pipeline page. For an explanation of development phases, visit our clinical development page.
Pipeline: IAVI-led candidatesHIV vaccine candidates
BG505 SOSIP gp140, adjuvanted (3M-052 AF + alum) — IAVI C107
HIVPartners
3M Corporate; Access to Advanced Health Institute; George Washington University; National Institute of Allergy and Infectious Diseases; Rockefeller University
BG505 SOSIP gp140, adjuvanted (3M-052 AF + alum) — IAVI C110
HIVPartners
3M Corporate; Access to Advanced Health Institute; Amsterdam UMC; Polymun Scientific GmbH
GRAd networked T-cell epitope
HIVPartners
Africa Health Research Institute; Bill & Melinda Gates Foundation; Collaboration for AIDS Vaccine Discovery Vaccine Immunology Statistical Center; Desmond Tutu Health Foundation; Fred Hutchinson Cancer Center; IAVI; Mutala Trust; Ragon Institute; ReiThera SRL; The National Institute for Communicable Diseases of South Africa
Tuberculosis (TB) vaccine candidates
MTBVAC (People living with and without HIV)
TuberculosisPartners
Biofabri S.L., HIV Vaccine Trials Network; National Institute of Allergy and Infectious Diseases; South African Tuberculosis Vaccine Initiative; Universidad de Zaragoza
Mini-protein for COVID-19 prophylaxis
IPD-52520
COVID-19Partners
Bill & Melinda Gates Foundation; Institute for Protein Design; SK bioscience